ARTICLES BY KATE HAMMEKE

• Where Bioprocessing Outsourcers Stand On Capacity Concerns

  10/11/2022

  Insights into bioprocessing outsourcers’ level of concern regarding current and upcoming available capacity, whether they are currently facing limits, and what they plan to do about a potential shortage.

• Outsourcing Differences By Company Size — Biologic Drug Substance Manufacturing

  6/14/2022

  ISR split the data from its most recent Biologic API CDMO Benchmarking report by large and non-large respondents to highlight the differences in outsourcing preferences and practices.

• Outsourcers Are Feeling Uneasy About Continuity of Supply

  4/14/2022

  Find out how COVID-19 complications have picked up from the first year, with more outsourcers experiencing bigger obstacles when it comes to manufacturing, specifically with drug product.

• Have CDMO Selection Criteria Changed Over The Past Five Years?

  3/16/2022

  New relationship dynamics between sponsors and CDMOs contribute to new trends appearing in the outsourced activities and services as well as the way CDMO selection decisions are made. ISR shares how CDMO selection criteria has changed over the past five years and links the attributes to the Life Science Leader’s CDMO Leadership Awards categories.

   
• What's Happening In Cell & Gene Therapy Development?

  2/8/2022

  This ISR report provides support and direction for innovative companies looking to outsource aspects of their cell and gene therapy manufacturing and development through shared research highlights.

• The Top CROs By Therapeutic Indication Share Strong Regulatory And Productivity Performance

  8/30/2013

  A recent market research study revealed that 59 percent of sponsors place therapeutic experiences as the top attribute that influences CRO selection.  Nice Insight’s outsourcing survey indicated the most popular therapeutic areas of focus for outsourced projects were cardiovascular disease, oncology, and infectious disease.

• Are Preferred Provider Agreements the Best Model For Outsourced Manufacturing?

  ISR has observed use of preferred provider agreements (PPAs) and the proportion of outsourcing allocated to preferred providers increase over the past three years.

• Outsourcing Success Requires Constant Evolution

  Industry Standard Research explains how Life Science Leader’s CMO Leadership Awards and market research data can help biopharma companies make more informed CMO selection decisions.

• Are Oral Dose Manufacturing Projects Becoming More Complicated?

  Are CDMOs evaluated on the same metrics for simple and complex oral dose manufacturing projects? Gain insight into data from ISR’s new report to provide answers to these questions and more.

• A Hypothetical Question About Outsourcing Services Leads To … More Questions?

  If you were in charge of establishing a bioprocessing contract manufacturing business, which service provider attributes would you implement to ensure your company’s success? Here's how peers in the industry responded.

• Areas Of Growth For Oral-Dose Outsourcing

  The long history and market dominance of oral dosage forms have made this category of drug product a good candidate for outsourced manufacturing. And, according to respondents* who participated in Industry Standard Research’s 2019 Oral Dosage Forms survey, there are no signs of oral-dose outsourcing letting up.

• COVID-19's Impact On Outsourced Manufacturing

  More than half of the biologic drug product outsourcers surveyed by ISR experienced outsourced manufacturing complications because of the pandemic. To understand how COVID-19 impacted the outsourced manufacturing sector, ISR answered a few questions on the topic in their annual contract development and manufacturing benchmarking studies.

• CMOs Continue To Exceed Sponsor Expectations

  ISR explains how the CMO Leadership Awards and the corresponding market research data can be used to make more informed CMO selection decisions and optimize operational and marketing strategies.

• Sponsor Challenges When Outsourcing Sterile Injectables

  Outsourcers of sterile injectable drug product were asked to identify their biggest challenge when outsourcing to CDMOs/CMOs. Here's a look at the resulting nearly four-way tie.

• Trends In Bioprocessing CDMO Selection

  Learn which CDMO characteristics experienced outsourcers value most from ISR’s Bioprocessing Market Trends and Outsourcing Dynamics report.